Food Allergy Treatment Market Projected to Surge to USD 12.57 Billion by 2032 on Rising Prevalence and Immunotherapy Advancements

Global Food Allergy Treatment Market Size and Forecast Insights from 2025 to 2032 with Emerging Therapy Trends

The food allergy treatment market, valued at USD 6.51 billion in 2024, is poised to reach USD 12.57 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.62% over the forecast period. Rising awareness about food allergies, increasing prevalence, and advancements in treatment therapies, particularly oral and epicutaneous immunotherapy, are transforming the market landscape. The growing demand for epinephrine auto-injectors for emergency anaphylaxis management also contributes significantly to market expansion.

In the U.S., which leads North America, the market was valued at USD 2.39 billion in 2024 and is projected to reach USD 4.43 billion by 2032, reflecting a CAGR of 8.06%. The country's dominance can be attributed to high food allergy prevalence, advanced healthcare infrastructure, early drug approvals such as Palforzia, and favorable reimbursement policies. According to FARE, approximately 33 million Americans live with at least one food allergy, including over 27 million adults, indicating a substantial patient pool for treatment therapies.

Gain Valuable Market Knowledge: Request a Sample Report: https://www.snsinsider.com/sample-request/7288

Key Factors Driving the Growth of the Food Allergy Treatment Market Globally and Regionally

Rising prevalence of food allergies continues to drive market growth, with peanuts, tree nuts, milk, shellfish, and eggs among the most common allergens. Severe allergic reactions, including anaphylaxis, are increasing the demand for both emergency interventions and long-term treatment approaches. Sedentary lifestyles, environmental factors, and dietary changes are contributing to the rising incidence of food allergies globally, particularly in children. The National Institutes of Health (NIH) reports that food allergies affect around 520 million people worldwide, with 3–10% of children and 10% of adults impacted.

Advancements in immunotherapy are accelerating market growth, offering solutions that go beyond immediate symptom relief. Oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) aim to desensitize patients and reduce allergen sensitivity over time. Palforzia, the first FDA-approved therapy for peanut allergy, and Omalizumab (Xolair), approved in February 2024 as adjunct therapy for IgE-mediated food allergies, exemplify innovations reshaping the treatment landscape. Continuous research and development for multiple allergen treatments are fueling investments and elevating immunotherapy as a rapidly growing trend.

High Treatment Costs and Accessibility Challenges Continue to Restrain the Market Despite Rising Demand

Despite positive market dynamics, high treatment costs remain a key restraint. Prolonged treatments, complex formulations, and frequent clinical visits in OIT and EPIT therapies lead to significant financial burdens. A recent study on probiotic peanut oral immunotherapy (PPOIT) reported healthcare costs per patient at approximately USD 9,355 over ten years, with over 50% attributed to treatment delivery. Additionally, epinephrine auto-injectors such as EpiPen, though lifesaving, are expensive, and insurance coverage varies, restricting access in many regions. These factors result in delayed or non-optimal treatment choices, particularly in low- and middle-income countries.

Drug Type Insights Highlight Epinephrine Dominance While Immunotherapy Segment Gains Rapid Traction

Epinephrine accounted for the largest market share of 42.11% in 2024, reflecting its status as the first-line treatment for severe allergic reactions, including anaphylaxis. Epinephrine auto-injectors remain widely prescribed due to their efficacy and rapid response capabilities. Hospitals, schools, and public spaces increasingly ensure epinephrine availability, supported by insurance schemes and awareness programs.

Meanwhile, immunotherapy is expected to register the fastest growth during the forecast period, driven by the demand for preventive and long-term treatments. Oral and epicutaneous immunotherapy offer the potential to desensitize patients, allowing safer exposure to allergens and reducing long-term allergic reactions, signaling a paradigm shift in allergy management.

Allergen Type Segmentation Shows Peanuts Leading Market Share with Expanding Interest in Tree Nuts

Peanut allergies dominated the market in 2024, holding 22.5% of the share due to their prevalence, particularly in children from North America and Europe. Peanut allergies are typically permanent and pose severe risks even at minimal exposure, necessitating emergency treatments and immunotherapy.

Tree nut allergies, including almonds, cashews, and walnuts, are projected to grow substantially. Increased awareness, advancements in immunotherapy targeting multiple allergens, and ongoing R&D efforts contribute to the segment’s expansion. Food labeling regulations and targeted therapy development further strengthen growth opportunities for tree nut allergy treatments.

Route of Administration Trends Reveal Parenteral Dominance and Rising Oral Immunotherapy Adoption

The parenteral route dominated the market in 2024 due to the use of intramuscular epinephrine auto-injectors, which provide rapid relief in emergency situations such as anaphylaxis. Hospitals and healthcare facilities prefer this route for immediate intervention and high efficacy.

The oral segment, primarily driven by oral immunotherapy (OIT), is expected to witness the fastest growth. FDA-approved treatments such as Palforzia enable controlled allergen exposure to build immune tolerance over time. Patients increasingly prefer non-invasive home-based therapies, positioning oral administration as a key trend shaping the future of food allergy treatment.

End-Use Segmentation Demonstrates Hospital Pharmacies Leading While Retail Pharmacies Gain Momentum

Hospital pharmacies led the market in 2024, offering specialized medications for emergency care and acute allergic reactions. They remain critical for administering parenteral medications and monitoring complex therapies.

Retail pharmacies are projected to grow fastest, providing convenient access to epinephrine auto-injectors, antihistamines, and immunotherapy maintenance medications. Counseling, medication management, and wider geographic presence in suburban and rural areas support this trend, reflecting patient preference for integrated and accessible care solutions.

Regional Analysis Highlights North America Dominance and Rapid Growth in Asia Pacific

North America held approximately 40.7% market share in 2024, driven by advanced healthcare infrastructure, high awareness, and early approvals for innovative therapies such as Palforzia and epinephrine auto-injectors. Nearly 32 million Americans have food allergies, including 6 million children, contributing to strong market demand.

Asia Pacific is expected to grow at the fastest CAGR of 9.30%, fueled by urbanization, westernization of diets, and increasing awareness. China, Japan, and India are key contributors, supported by healthcare investment, improved diagnostics, and gradual adoption of immunotherapy.

Europe shows substantial growth potential due to awareness campaigns, robust regulatory frameworks, and a high prevalence of clinical trials. Countries such as the U.K., Germany, and France lead developments in immunotherapy adoption and emergency medication accessibility.

Latin America and MEA regions are witnessing moderate growth, constrained by underdiagnosis and limited specialized care. However, expanding healthcare investment, educational campaigns, and urbanization are expected to sustain steady market development.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report: https://www.snsinsider.com/reports/food-allergy-treatment-market-7288

Key Players Shaping the Global Food Allergy Treatment Market Landscape

Aimmune Therapeutics, DBV Technologies, ALK-Abelló, Stallergenes Greer, Camallergy, Alladapt Immunotherapeutics, Aravax, Intrommune Therapeutics, Prota Therapeutics, Regeneron Pharmaceuticals

Recent Developments Highlight New Strategies and Clinical Advancements in Food Allergy Treatments

In January 2025, DBV Technologies reported positive 24-month data from the Open-Label Extension of its Phase 3 EPITOPE trial assessing VIASKIN Peanut 250 µg (VP250) in children aged 1–3 years, demonstrating sustained improvement through 36 months.

In June 2024, ALK-Abelló launched Allergy+, a strategy aimed at expanding leadership in food allergy and anaphylaxis treatment, alongside innovation in adjacent allergic diseases, signaling continued investment and market evolution.

Future Outlook for the Global Food Allergy Treatment Market

The global food allergy treatment market is expected to continue robust growth through 2032, driven by increasing prevalence, immunotherapy innovations, and public health initiatives. Expansion of oral and epicutaneous immunotherapy, alongside broader adoption of epinephrine auto-injectors, will enhance treatment accessibility and patient outcomes. Developing regions will witness accelerated adoption as awareness, healthcare infrastructure, and regulatory support improve.

Conclusion on Global Food Allergy Treatment Market Growth Prospects

The food allergy treatment market is experiencing a transformative phase, with rising incidences, innovative therapies, and increasing investments driving sustained growth. Key players, regulatory approvals, and evolving treatment strategies are shaping the market’s trajectory toward better patient care, accessibility, and long-term management solutions globally.

Other Trending Reports

Disposable Trocars Market

Blood Processing Devices and Consumables Market

Non-alcoholic Steatohepatitis Biomarkers Market

Medical Ceramics Market